OXFORD, England--(BUSINESS WIRE)--Specialty pharma company, Glide Pharma, today announced it has raised a further £2.2 million to develop the Glide SDI™ - Solid Dose Injector. Despite the harsh economic climate, existing investors, led by the Oxford Technology VCTs, were quick to respond and were joined by a handful of new investors in a fully subscribed fundraising. The funding comes at an exciting stage in the company’s development as it targets the biologics injectables market which is forecast to grow to over $50 billion by 2012. The Glide SDI is now in feasibility studies for delivering vaccines and biopharmaceuticals with five partners, three of which are new partners for 2008.
